- Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients
- In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market
- The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association International Conference(R) 2024 (AAIC(R)) in Philadelphia. Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of the company detailed these findings, as well as the scientific community’s response and the company’s future plans, during a recent episode of IBN’s Bell2Bell Podcast with Stuart Smith, recorded live at the AAIC.
Dr. Maccecchini explained that this was a short-term study with 360 participants, all in the early stages of Alzheimer’s disease. The response to buntanetap was excellent, as the drug candidate was shown to be at least three times better than the standard of care available in the market. The results were welcomed by…
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN